Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?

Chest

Volumn 126, Issue 3, 2004, Pages 755-760

  Aquino, Suzanne L ^a   Fischman, Alan J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer staging; Carcinoma, non small cell lung; Lung cancer; Neoplasms; Radiography, thoracic; Tomography, emission computed

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; DIAGNOSTIC AGENT;

ADULT; AGED; CANCER STAGING; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NODULE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX SCINTISCANNING; WHOLE BODY SCINTISCANNING; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LABORATORY DIAGNOSIS; LUNG COIN LESION; LUNG TUMOR; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; THORAX TUMOR; WHOLE BODY COUNTING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COIN LESION, PULMONARY; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE-BODY COUNTING;

EID: 4544355367     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3.755     Document Type: Article

References (20)

1. Pretreatment evaluation of non-small-cell lung cancer: the American Thoracic Society and the European Respiratory Society. Am J Respir Crit Care Med 1997; 156:320-332
2. Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123:1478-1565
3. Pieterman RM, van Putten JWG, Mewuzelar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000; 343:254-261
4. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573-1582
5. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. The Ann Thorac Surg 1998; 66:886-892
6. Marom E, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809
7. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-1717
8. Trends in lung cancer morbidity and mortality. American Lung Association Epidemiology and Statistics Unit, Research and Scientific Affairs, June 2003. Available at: http://www. lungusa.org/atf/cf/. Accessed June 17, 2004
9. Gupta NC, Tamin WJ, Graeber GG, et al. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001; 120:521-527
10. Grant D, Edwards D, Goldstar P. Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer. Thorax 1988; 43:883-886
11. MacManus MP, Hicks R, Matthews, JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50:287-293
12. Charania, M. Aquino S, Fischman A. Clinical impact of whole-body vs thoracic PET for staging patients with lung cancer [abstract]. J Nucl Med 2003; 44(suppl):392P
13. Tanaka K, Kubota K, Kodama T, et al. Extrathoracic staging is not necessary for non-small-cell lung cancer with clinical stage T1-2N0. Ann Thorac Surg 1999; 68:1039-1042
14. Tack D, De Maertelaer V, Gevenois PA. Low dose enhanced multidetector CT of patients with suspected renal colic. AJR Am J Roentgenol 2003; 180:305-311
15. Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170:1369-1373
16. Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med 1997; 38:1382-1383
17. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016-1020
18. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38:261-266
19. Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 2002; 43:876-881
20. Matthies A, Hickeson M, Cuchiara A, et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-875